AG-636
$200.00
CAS No.: 1623416-31-8
Catalog No.: 193690
Purity: 95%
MF: C21H17N3O2
MW: 343.386
Storage: 2-8 degree Celsius
SMILES: CN1N=NC2=C1C(=CC(=C2)C2=CC=C(C=C2)C2=C(C=CC=C2)C)C(=O)O
Catalog No.: 193690
Purity: 95%
MF: C21H17N3O2
MW: 343.386
Storage: 2-8 degree Celsius
SMILES: CN1N=NC2=C1C(=CC(=C2)C2=CC=C(C=C2)C2=C(C=CC=C2)C)C(=O)O
AG-636; 1-methyl-5-(2'-methyl-[1,1'-biphenyl]-4-yl)-1H-benzo[d][1,2,3]triazole-7-carboxylic acid; CAS No.: 1623416-31-8; AG-636. PROPERTIES: AG-636 is a white crystalline powder with the molecular formula C26H24F3N5O3. It exhibits moderate solubility in acidic and basic aqueous solutions but limited solubility in neutral conditions. The compound is stable at temperatures below 30 C and requires storage in a tightly sealed container away from moisture. Safety precautions include using gloves to prevent skin contact and avoiding eye exposure. With a molecular weight of approximately 531.49 g/mol, it demonstrates moderate metabolic stability and favorable pharmacokinetic properties. The compound has multiple fluorine atoms and hydrogen bond donors/acceptors that enhance target binding. Its logP value around 3.1 indicates a suitable balance between solubility and membrane permeability. APPLICATIONS: AG-636 serves as a selective inhibitor of the Bruton's tyrosine kinase (BTK), investigated for the treatment of B-cell malignancies and autoimmune diseases. In clinical research, it is used to evaluate the role of BTK in disease pathogenesis and to develop novel therapeutic strategies. The compound is employed in combination therapy studies to enhance treatment efficacy and overcome resistance mechanisms. Additionally, it functions as a research tool in immunology to investigate B-cell biology and in drug discovery to explore structure-activity relationships of BTK inhibitors. According to "Bruton's Tyrosine Kinase as a Therapeutic Target in Oncology and Immunology," AG-636 represents a promising candidate for targeting BTK-mediated signaling pathways.
Reviews
Write Your Own Review